Massachusetts GIC ends obesity-only GLP-1 coverage and shuts down the Vida prescribing requirement

Massachusetts' Group Insurance Commission (GIC), which covers more than 220,000 subscribers and 460,000 members, ended pharmacy coverage of GLP-1 medicines prescribed solely for weight loss as of July 1, 2026 ^[1]. At the same time, the arrangement that let Vida Health clinicians prescribe those drugs to GIC members ended ^[2].

For non-Medicare GIC members, coverage for GLP-1s prescribed only for obesity ended June 30, 2026 ^[2]. Starting July 1, members who want these medicines work directly with their own doctor, and prescriptions require prior authorization through CVS Caremark, the plan's pharmacy benefit manager ^[2].

What is and is not covered

The GIC says medicines used only for weight loss — naming Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda — are no longer covered by the pharmacy benefit, and members filling them for that reason pay the full cost out of pocket ^[1].

Coverage can still be approved when a prescription is tied to a qualifying FDA-approved condition and the prescriber submits a request that is reviewed before a decision ^[1]. As of June 17, 2026, the GIC listed three qualifying conditions, and said the list is subject to change at any time ^[1]:

• Non-cirrhotic MASH/NASH with moderate to advanced (F2–F3) fibrosis, with no BMI requirement because that indication was approved in both overweight/obese and non-overweight populations ^[1].
• Risk reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, requiring a baseline BMI of at least 27 kg/m². The GIC defines established cardiovascular disease as a previous heart attack, previous stroke, symptomatic peripheral arterial disease, or a prior revascularization procedure ^[1].
• Moderate to severe obstructive sleep apnea in adults with obesity, requiring a current BMI of at least 30 kg/m² ^[1].

GLP-1s used for diabetes are not affected. The GIC says coverage for drugs such as Ozempic (semaglutide) and Mounjaro (tirzepatide) prescribed for diabetes continues as it does today, with no special program enrollment required ^[1].

The Vida change

Before July 1, Vida was part of how GIC members accessed weight-loss medicines ^[1]. After July 1, members can no longer schedule visits with Vida physicians or nurse practitioners, and Vida no longer prescribes anti-obesity medicines, including GLP-1s ^[1]. Vida still offers health coaching, nutrition support, lifestyle guidance and registered dietitian services, and directs members to their existing prescriber or, if they do not have one, to the GIC network directory ^[1][2]. Some members, including those with diabetes or certain complex medical conditions, were never eligible for Vida; the GIC says those members can keep working with their regular doctor, who can still request coverage if appropriate ^[1].

The GIC's stated steps for current GLP-1 users are to talk with a PCP or specialist outside Vida about whether the medicine is being used for a condition that may qualify, confirm coverage, and ask questions if unsure ^[1]. Coverage questions go to CVS Caremark at (877) 876-7214 ^[1].

Why it matters for patients

This is a benefit-design change, not a change in the drugs themselves. For a GIC member taking Wegovy or Zepbound purely for weight, the practical result is that the plan no longer pays, and the retail cost falls to the member unless a prescriber documents a qualifying diagnosis ^[1]. The same medicine can be covered for one person and not another depending on the diagnosis on the prior authorization request.

It also changes who writes the prescription. Members who had been seeing Vida clinicians now need a regular prescriber to handle both the prescription and the prior authorization paperwork, which can take time to arrange ^[1][2].

What happens next

Medicare GIC members have a longer runway: current GIC coverage of GLP-1s prescribed for obesity continues through December 31, 2026 ^[2]. After that, coverage generally continues only for members meeting CMS-approved clinical criteria, with coverage remaining for diabetes use and for members with a BMI of 27 or higher who also have an FDA-approved comorbidity ^[2].

Separately, Mass Retirees reported that Medicare was expected to launch a temporary "GLP-1 Bridge" demonstration beginning July 1, 2026, offering eligible Part D beneficiaries certain weight-loss GLP-1s for a flat copay of about $50 a month, with Wegovy (injectable and tablet), Zepbound KwikPen and Foundayo (orforglipron) expected to be included and Ozempic excluded ^[2]. Expected criteria include a BMI of 35 or higher, 30 or higher with qualifying conditions, or 27 or higher with pre-diabetes or certain cardiovascular conditions, with members already on treatment possibly qualifying using their starting BMI ^[2]. Mass Retirees stressed that eligibility, drug list, costs and processes were still being finalized and could change ^[2]. Final federal details are not established in these sources.